Research programme: macrocyclic peptide therapeutics- PeptiDream/ Kleo Pharmaceuticals

Drug Profile

Research programme: macrocyclic peptide therapeutics- PeptiDream/ Kleo Pharmaceuticals

Alternative Names: Macrocyclic peptide therapeutics- PeptiDream/ Kleo Pharmaceuticals

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kleo Pharmaceuticals; PeptiDream
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 18 Jul 2017 PeptiDream and Kleo Pharmaceuticals agree and develop small molecule immunotherapies for Cancer
  • 18 Jul 2017 Early research in Cancer in Japan (unspecified route)
  • 18 Jul 2017 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top